A Comparison of Two Drug-Eluting Stents Yields a Clear Winner

Overall rates of target-lesion failure were lower in everolimus-eluting stent recipients than in paclitaxel-eluting stent recipients.

In this prospective, multicenter, single-blind trial, 3687 patients undergoing elective stent implantation were randomized in a 2:1 ratio to receive second-generation everolimus-eluting stents (EES; XIENCE V) or first-generation paclitaxel-eluting stents (PES; TAXUS Express²). The study was sponsored by the EES manufacturer.

The primary composite endpoint of cardiac death, target-vessel myocardial infarction (MI), or ischemia-driven target-vessel revascularization at 1 year occurred in 4.2% of patients in the EES group versus 6.8% of those in the PES group (odds ratio, 0.62; P=0.001). Stent thrombosis (at 24 hours, 30 days, and 1 year) also occurred less frequently in the EES group than in the PES group (0.2% vs.0.8% overall; P=0.004). Targe…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI